## Expert Assessment: SASP Modulation for Neurodegeneration
### Druggability
**IL-1β**: Highly druggable with established agents—Anakinra (IL-1Ra), Canakinumab (anti-IL-1β antibody). Both FDA-approved for inflammatory conditions. Critical limitation: CNS penetration is poor, requiring significant formulation advances for brain diseases.
**NFKB1/p50**: Transcription factors are traditionally "undruggable." Indirect targeting through IKK complexes (evidence for IKKβ inhibitors) or cofactor disruption (BRG1, HDAC6) represents the viable path, though specificity remains challenging.
**BDNF preservation**: Indirect approaches only—TrkB agonists (BDNF mimetics) exist but none in late-stage neurology trials. This target is more constraint than actionable handle.
### Competitive Landscape
| Approach | Stage | Lead Programs |
|----------|-------|---------------|
| **Senolytics** (Dasatinib/Quercetin) | Phase 2 | Mayo Clinic AD trial (NCT04685590); multiple IPF studies |
| **UBX0101** (Unity Biotech) | Ph2 failed | OA program discontinued, pipeline pivoting |
| **JAK inhibitors** (Ruxolitinib) | Repurposed | Myelofibrosis; off-label SASP modulation |
| **Rapamycin/mTOR** | Preclinical | FOXO activation reduces SASP in models |
**SASP modulation sits earlier in the value chain**—theoretically elegant but less industrialized than senolytics.
### Key Practical Concerns
1. **Cell-type specificity remains unsolved**: Distinguishing microglial SASP from astrocyte SASP versus neuronal NF-κB signaling cannot be achieved with current pharmacologic tools.
2. **Timing paradox**: SASP may facilitate early protein clearance; blanket suppression could impair neuroprotective homeostasis.
3. **Pericytes and vasculature**: Emerging evidence (Cell 2024) implicates vascular senescence independently—adding complexity to single-pathway strategies.
### Verdict
Modulating rather than eliminating senescent cells is mechanistically appealing and avoids the "collateral damage" risks of senolytics. However, translatability hinges on CNS-penetrant IL-1 pathway inhibitors